lundi 14 novembre 2016

Onco Actu du 14 novembre 2016

1. Biologie

Gene linked to brain defect could point to a new brain tumour drug target [Cancer Research UK]

2. Etiologie

Food emulsifiers and cancer: Fear-mongering stories needed to dig deeper than the news release [HealthNewsReview]

3.1 Tabac

Cigarette Smoking In The U.S. Continues To Fall [NPR]

3.1.1 Tabac - e-cigs

Teen vapers 'more likely to take up smoking' [NHS Choices]

4. Dépistage, diagnostic et pronostic

Sponge on a string test could replace endoscopies [Cancer Research UK]

4.5 Dép., diag. & prono. - Colorectal

Cosmo shares jump on colonoscopy trial results [Reuters]

4.9 Dép., diag. & prono. - Sein

Personalised breast cancer programme launches in Cambridge [Cancer Research UK]

Take multiple biopsies in studies of personalised breast cancer treatments, study says [Institute of Cancer Research]

5. Traitements

Does efficacy require toxicity, or is it time to reconsider presurgical endocrine therapy for estrogen-receptor-positive breast cancer? [Mass General Hospital]

How Alzheimer’s bad guy amyloid is being harnessed to fight cancer [FierceBiotech]

5.12 Immunothérapies

ImmunoGen to Present Preclinical Data Highlighting Potential of Combining Mirvetuximab Soravtansine with an Immune Checkpoint Inhibitor at SITC 2016 Annual Meeting [ImmunoGen]

Merck’s KEYTRUDA® (pembrolizumab) Significantly Improves Overall Survival Compared to Chemotherapy in Previously Treated Patients with Advanced Bladder (Urothelial) Cancer [Merck]

Weight loss condition provides clue to why some immunotherapy treatments fail [Cancer Research UK]

Stand Up To Cancer Launches $7.5 Million in Innovative Research Grants Focusing on Immuno-Oncology, Supported by a Grant from Bristol-Myers Squibb [AACR]

Policy Issues in the Clinical Development and Use of Immunotherapy for Cancer Treatment: Proceedings of a Workshop (2016) [National Academies Press]

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck [Now@NEJM]

5.12.1 Immunothérapies - partenariats

Halozyme Announces Broad Clinical Collaboration Agreement To Evaluate PEGPH20 And Tecentriq In Up To Eight Tumor Types [Halozyme]

Bristol-Myers Squibb and Infinity to collaborate on Opdivo (nivolumab) plus IPI-549 solid tumours study [European Pharmaceutical Review]

Bristol-Myers, Johns Hopkins pen I/O research pact [FierceBiotech]

5.12.2 Immunothérapies - CAR-T

FDA lifts clinical hold on Adaptimmune cancer trial [FierceBiotech]

5.12.3 Immunothérapies-combinaisons

Phase 1/2 Data Combining Urelumab with Opdivo (nivolumab) in Hematologic and Solid Tumors Suggest Increased Antitumor Effect in Patients with Melanoma [BMS]

Interim Phase 1/2 Data Show Encouraging Clinical Benefit for Lirilumab in Combination With Opdivo (nivolumab) in Patients With Advanced Platinum Refractory Squamous Cell Carcinoma of the Head and Neck [BMS]

Opdivo (nivolumab) and Yervoy (ipilimumab) Regimen Shows Promising Efficacy and Safety in Previously Treated Patients With Advanced Form of Bladder Cancer [BMS]

5.12.4 Immunothérapies - Essais

Opdivo (nivolumab) Demonstrates Overall Survival Benefit in Patients With Unresectable Advanced or Recurrent Gastric Cancer in Phase 3 Study [BMS]

Bristol-Myers scores fresh bragging rights with PhIII gastric cancer success for Opdivo [EndPoints]

Bristol-Myers' Opdivo succeeds in key stomach cancer study [Reuters]

5.2 Pharma

Novartis leukemia drug wins FDA priority review [Reuters]

AstraZeneca axes another R&D track on durvalumab after once again falling behind rivals [EndPoints]

AstraZeneca drops early head and neck cancer drug plans [Reuters]

5.2.3 Pharma - économie

Which drug makers do a good job getting poor patients access to their medicines? [STAT]

5.3.4 Traitements - AMM (FDA, EMA)

Bristol-Myers Squibb’s Opdivo® (nivolumab) is the First Immuno-Oncology Treatment to Receive FDA Approval Based on Overall Survival in Head and Neck Cancer [BMS]

Nivolumab for SCCHN [FDA]

Use of Immunotherapeutic Expanded to Fifth Type of Cancer [AACR]

5.4 Traitements - Economie

Price cuts pave the way for routine access to breast and lung cancer drugs [NICE]

6. Lutte contre les cancers

Breaking the link between cancer and poverty [BBC News]

NCRI Cancer Conference 2016: Day 4 – liver cancer, obesity, immunotherapy poo predictions and more [Cancer Research UK]

Symposium Brings Rising Global Cancer Burden into Focus [NCI]

How to enrol your dog in a cancer-drug trial [The Economist]

6.1 Observation

Age may not affect breast reconstruction complications [Reuters]

Vitamin D levels tied to breast cancer survival [Reuters]

6.10.1 Politiques (USA)

Statement from the American Association for Cancer Research on the Presidential Election [AACR]

U.S. consumers will want Trump, Congress to take on drug prices [Reuters]

6.11 Patients

My cancer diary: ‘One of the most difficult days’ [The Guardian]

Targets matter – because a day with cancer worries feels like a year [The Guardian]

6.6 Publications

Open peer review finds more takers [Nature]

6.7.1 Bioinformatique

IBM Watson, Broad Institute team up on $50M cancer drug resistance project [FierceBiotech]

6.8 Communication

The secret life of an oncologist: witnessing the most painful and intimate moments of life [The Guardian]